Skip to main content
SpringerLink
Log in

Variability of tumor response to chemotherapy I. Contribution of host heterogeneity

  • Original Articles
  • Tumour Response, Host Heterogeneity
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Host factors that might be associated with the variable response of tumors to effective chemotherapy were studied in B6C3F1 mice bearing transplanted mammary adenocarcinoma 16/C tumors and treated with melphalan. Tumor response ranged from regression to an unpalpable size to growth under treatment. That biochemical resistance of the cell population was not primarily responsible for the variability was demonstrated by passage of responsive and nonresponsive tumors into new hosts followed by treatment with melphalan. When the implanted subcutaneous tumor weighed 1.0 g or less (usually 12 to 13 days postimplant), both the plasma levels of melphalan and the variability in plasma levels were similar to those observed in tumor-free mice. With tumor progression beyond 1.0 g, an increase in mean plasma levels and in variability, but not in plasma half-life, was observed. A correlation between the dose of melphalan administered, the schedule, and the percentage of tumor responses was found. There was no correlation between the plasma levels in individual mice following a given dose of melphalan and subsequent tumor response. Also, there was no correlation between the plasma levels of melphalan in individual mice following the second, third or fourth treatment in a multiple-dose treatment schedule and the response of the tumor in that mouse to previous treatments. Prior therapy (1, 2 or 3 doses administered 4 days apart) either prevented the increase in plasma levels that occurred in mice bearing untreated advanced tumors or reduced the plasma level (and the variability) to approximately that found in tumor-free mice. Whether this was a direct result of the effects of melphalan on the host or an indirect result of tumor inhibition is not known. A similar study in tumor-free mice indicated that prior treatment had only minimal effects on subsequent plasma levels. These studies indicate that heterogeneity of the host was not a major factor in variable tumor response if therapy was initiated when the tumors weighed 1.0 g or less.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adair CG, Bridges JM, Desai ZR (1986) Renal function in the elimination of oral melphalan in patients with multiple myeloma. Cancer Chemother Pharmacol 17: 185

    Google Scholar 

  2. Alberts DS, Chang SY, Chen H-SG, Moon TE, Evans TL, Furner RL, Himmelstein K, Gross JF (1979) Kinetics of intravenous melphalan. Clin Pharmacol Ther 26: 73

    Google Scholar 

  3. Alberts DS, Chang SY, Chen H-SG, Evans TL, Moon TE (1979) Oral melphalan kinetics. Clin Pharmacol Ther 26: 737

    Google Scholar 

  4. Alberts DS, Chen H-SG, Benz D, Mason NL (1981) Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. Br J Cancer 43: 330

    Google Scholar 

  5. Baguley BC, Falkenhaug E-M (1971) Plasma half-life of cytosine arabinoside (NSC 63878) in patients treated for acute myeloblastic leukemia. Cancer Chemother Rep. 55: 291

    Google Scholar 

  6. Bartošek I, Donelli MG, Guaitani A (1974) Modification of drug metabolism induced in the host by the presence of a tumor. In: Mathé G, Oldham RK (eds) Complications of cancer chemotherapy. Springer, Berlin Heidelberg New York. Recent results in cancer research, vol 49, p 95

    Google Scholar 

  7. Bazare J Jr, Leamons ML, Young JF (1981) Sampling methods for pharmacokinetic studies in the mouse. J Pharmacol Methods 5: 99

    Google Scholar 

  8. Brade WP, Freireich EJ, Goldin A (1984) Dose-response relationship in experimental and clinical oncology. Cancer Treat Rev 11: 279

    Google Scholar 

  9. Broggini M, Colombo T, Garattini S, Donelli MG (1980) Influence of tumor on adriamycin concentration in blood cells. Cancer Chemother Pharmacol 4: 209

    Google Scholar 

  10. Byington KH, Bowe CC, McKinsey DS (1980) Biliary excretion of melphalan by control and anuric rats. Biochemical Pharmacol 29: 2518

    Google Scholar 

  11. Chang SY, Alberts DS, Melnick LR, Walson PD, Salmon SE (1978) High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci 67: 679

    Google Scholar 

  12. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr (1978) Biology and therapeutic response of a mouse mamary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 62: 1471

    Google Scholar 

  13. Cornwell GG III, Pajak TF, McIntyre OR, Kochwa S, Dosik H (1982) Influence of renal failure on myelosuppresive effects of melphalan: Cancer and Leukemia Group B experience. Cancer Treat Rep 66: 475

    Google Scholar 

  14. Costa G (1977) Cachexia, the metabolic component of neoplastic disease. Cancer Res 37: 2327

    Google Scholar 

  15. Erlichman C, Donehower RC, Chabner BA (1980) The practical benefits of pharmacokinetics in the use of antineoplastic agents. Cancer Chemother Pharamacol 4: 139

    Google Scholar 

  16. Evans TL, Chang SY, Alberts DS, Sipes IG, Brendel K (1982) In vitro degradation of L-phenylalanine mustard (L-PAM). Cancer Chemother Pharmacol 8: 175

    Google Scholar 

  17. Farmer PB, Newell DR (1983) Alkylating agents: In: Ames MM, Powis G, Kovach JS (eds) Pharmacokinetics of anticancer drugs in humans. Elsevier, Amsterdam, p 77

    Google Scholar 

  18. Fisher B, Saffer EA (1982) Heterogeneity of tumor growth during chemo-immunotherapy: Observations on a murine model. In: Fidler IJ, White RJ (eds) Design of models for testing cancer therapeutic agents. Van Nostrand/Reinhold, New York, p 114

    Google Scholar 

  19. Furner RL, Brown RK (1980) L-Phenylalanine mustard (L-PAM): the first 25 years. Cancer Treat Rep 64: 559

    Google Scholar 

  20. Furner RL, Mellett LB, Brown RK, Duncan G (1976) A method for the measurement of L-phenylalanine mustard in the mouse and dog by high pressure liquid chromatography. Drug Metab Dispos 4: 577

    Google Scholar 

  21. Furner RL, Brown RK, Duncan G (1977) Pharmacokinetics of the absorption, distribution and elimination of melphalan in the dog. Cancer Treat Rep 61: 1637

    Google Scholar 

  22. Garattini S (1983) Is it necessary to measure plasma levels of anticancer drugs? Biomed Pharmacother 37: 209

    Google Scholar 

  23. Gessner T, Robert J, Bolanowska W, Hoerni B, Durand M, Preisler H, Rustum J (1981) Effects of prior therapy on plasma levels of adriamycin during subsequent therapy. J Med 12: 183

    Google Scholar 

  24. Harris AL, Potter C, Bunch C, Boutagy J, Harvey DJ, Grahame-Smith DG (1979) Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. Br J Clin Pharmacol 8: 219

    Google Scholar 

  25. Harrison SD Jr, Giles HD, Denine EP (1980) Antitumor drug toxicity in tumor-free and tumor-bearing mice. Cancer Chemother Pharmacol 4: 199

    Google Scholar 

  26. Heppner G, Miller BE (1982) Biological variability of mouse mammary neoplasms. In: Fidler IJ, White RJ (eds) Design of models for testing cancer therapeutic agents. Van Nostrand/Reinhold, New York, p 37

    Google Scholar 

  27. Laster WR, Schabel FM Jr, Skipper HE, Wilcox WS, Thomson JR (1961) Experimental evaluation of potential anticancer agents: IV. Host weight loss as it relates to false positive in drug evaluation. Cancer Res 21: 895

    Google Scholar 

  28. Lundholm K, Edström S, Ekman L, Karlberg I, Bylund A-C, Scherstén T (1978) A comparative study of the influence of malignant tumor on host metabolism in mice and man. Cancer 42: 453

    Google Scholar 

  29. Metzler CM, Elfring GK, McEwen AJ (1974) A package of computer programs for phamacokinetics. Biometrics 30: 562

    Google Scholar 

  30. Nelson AJ, Hokanson JA, Jenkins VK (1982) Role of the host in the variable chemotherapeutic response of advanced Ridgway osteogenic sarcoma. Cancer Chemother Pharmacol 9: 148

    Google Scholar 

  31. Ninane J, Baurain R, deSelys A, Trouet A, Cornu G (1985) High dose melphalan in children with malignant disease. Cancer Chemother Pharmacol 15: 263

    Google Scholar 

  32. Noker PE, Simpson-Herren L, Wagoner SD (1985) Heterogeneity of response of mammary adenocarcinoma 16/C (mam ad 16/C) to melphalan (L-PAM) (NSC 8806). Proc. Am Assoc Cancer Res 25: 339

    Google Scholar 

  33. Piazza E, Broggini M, Trabattoni A, Natale N, Libretti A, Donelli MG (1981) Adriamycin distribution in plasma and blood cells of cancer patients with altered hematocrit. Eur J Cancer Clin Oncol 17: 1089

    Google Scholar 

  34. Powis G (1985) Anticancer drug pharmacokinetics. Cancer Chemother Pharmacol 14: 177

    Google Scholar 

  35. Powis G, Ames MM, Kovach JS (1983) Dose dependent pharmacokinetics of anticancer drugs. In: Ames MM, Pawis G, Kovach SJ (eds) Phamacokinetics of anticancer agents in humans. Elsevier, Amsterdam, p 49

    Google Scholar 

  36. Priesler HV, Gessner T, Azarnia H, Bolanowska W, Epstein J, Early AP, D'Arrigo P, Vogler R, Winton L, Chervenik P, Joyce R, Lee H, Steele R, Goldberg J, Gottlieb A, Bowman G, Miller K, Grunwald H, Larson R, Brennan J (1984) Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 12: 125

    Google Scholar 

  37. Rockwell S, Moulder JE, Martin DF (1984) Tumor-to-tumor variability in the hypoxic fractions of experimental rodent tumors. Radiother Oncol 2: 57

    Google Scholar 

  38. Rosso R, Donelli MG, Franchi G, Garattini S (1971) Impairment of drug metabolism in tumor-bearing animals. Eur J Cancer 7: 565

    Google Scholar 

  39. Schabel FM Jr, Griswold DP Jr, Corbett TH, Laster WR, Lloyd HH, Rose WC (1982) Variable responses of advanced solid tumors of mice to treatment with anticancer drugs. In: Fidler IJ, White RJ (eds) Design of models for testing cancer therapeutic agents. Van Nostrand/Reinhold, New York, p 95

    Google Scholar 

  40. Sedman AJ, Wagner JG (1976) CSTRIP, a FORTRAN IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 65: 1006

    Google Scholar 

  41. Sjöqvist F (1985) Interindividual differences in drug responses. An overview. In: Rowland M (ed) Variability in drug therapy: Description, estimation and control. Raven, New York, p 1

    Google Scholar 

  42. Spreafico F, Donelli MG, Vecchi A, Bossi A, Garattini S (1974) Factors modifying the activity and toxicity of anticancer agents. In: Mathé G, Oldham RK (eds) Complications of cancer chemotherapy. Springer, Berlin Heidelberg New York, Recent results in cancer research vol 49 p 88

    Google Scholar 

  43. Tattersall MHN, Jarman M, Newlands ES, Holyhead L, Milsteads RAV, Weinberg A (1978) Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 14: 507

    Google Scholar 

  44. Tropé C (1982) Different susceptibilities of tumor cell subpopulations to cytotoxic agents. In: Fidler IJ, White RJ (eds) Design of models for testing cancer therapeutic agents. Van Nostrand/Reinhold, New York, p 64

    Google Scholar 

  45. Van Slooten H, Moolenaar AJ, Van Seters AP, Smeenk D (1984) The treatment of adrenocortical carcinoma with o,p′-DDD: Prognostic simplifications of serum level monitoring. Eur J Cancer Clin Oncol 20:47

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biochemistry Department, Southern Research Institute, 35255-5305, Birmingham, AL, USA

    L. Simpson-Herren, P. E. Noker & S. D. Wagoner

Authors
  1. L. Simpson-Herren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. E. Noker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. D. Wagoner
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by PHS grant RO1 CA37132 awarded by the National Cancer Institute, NIH, DHHS

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simpson-Herren, L., Noker, P.E. & Wagoner, S.D. Variability of tumor response to chemotherapy I. Contribution of host heterogeneity. Cancer Chemother. Pharmacol. 20, 297–304 (1987). https://doi.org/10.1007/BF00262580

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00262580

Keywords

Search

Navigation